deltatrials
Completed PHASE3 NCT00288002

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer

Sponsor: GBG Forschungs GmbH

Conditions Breast Cancer
Interventions adjuvant therapy capecitabine conventional surgery cyclophosphamide docetaxel epirubicin hydrochloride neoadjuvant therapy trastuzumab
Updated 6 times since 2017 Last updated: Aug 23, 2013 Started: Jan 31, 2005

Listed as NCT00288002, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by GBG Forschungs GmbH, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GBG Forschungs GmbH
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Neu-Isenburg, Germany